|
|
|
News For QGEN From The Last 14 Days Check below for free stories on QGEN the last two weeks. |
|
|
| June 7, 2013 | | 07:26 EDT |  | QGEN | QIAGEN expands offering of assay panels for next-generation sequencing
 Subscribe for More Information | | | June 6, 2013 | | 15:11 EDT | | QGEN | QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike deal
QIAGEN (QGEN) said its full-year earnings view will not be changed following an announcement that Quest Diagnostics (DGX) and Hologic (HOLX) reached a supply agreement. WHAT'S NEW: Earlier today, Quest Diagnostics and Hologic announced a non-exclusive agreement for Quest to more broadly offer Hologic's APTIMA family of testing products. Hologic's APTIMA line includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. WHAT'S NOTABLE: Following the announcement, QIAGEN, which competes with Hologic in the diagnostic product space, said that a "U.S. reference laboratory customer" of its products made public a deal to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN said the customer would continue to offer its HPV-related products as well. QIAGEN said that it saw no need to revise its full-year 2013 guidance based on the development. The company also noted that sales related to this development represent less than 2% of the company's anticipated 2014 sales, and HPV screening in the U.S. is expected to represent less than 10% of the company's 2014 total net sales. PRICE ACTION: Hologic advanced following news of its agreement with Quest, and its shares are up over 2% in afternoon trade. QIAGEN shares are off their best levels, but still higher by about 0.5%. | | | 14:33 EDT | | QGEN | QIAGEN says U.S. reference lab decision will not change FY13 outlook
QIAGEN announced that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has made public on June 6 a new non-exclusive agreement to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN has been informed that its HPV-related products will continue to be offered by this customer. QIAGEN sees no need at this time to revise its guidance for FY13, and expects that sales related to this development represent less than 2% of its anticipated total net sales for FY14. QIAGEN further expects that sales related to products used in HPV screening in the U.S. to represent less than 10% of total net sales in FY14. | |
|
|
|
|
|
|
